ClinicalTrials.gg
WithdrawnNCT02634970CANARIUpdated Feb 15, 2017

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

A Phase 4 interventional study of Ranibizumab in Wet Age-related Macular Degeneration (Wet AMD), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

There are limited prospective data regarding the potential benefit and risks associated with switching between anti-VEGF therapies in patients with nAMD who have initially achieved a favorable response to the first anti-VEGF therapy used but subsequently have evidence of increasing disease activity despite continuation of therapy. This study will fill this knowledge gap by prospectively evaluating the effectiveness and safety of switching from aflibercept to ranibizumab in nAMD patients that have non - sustained response to initial treatment with aflibercept.

02

Conditions studied

  • Wet Age-related Macular Degeneration (Wet AMD)

Keywords

  • wet AMD, ranibizumab, aflibercept, neovascularization
03

In context

Neovascularization, Pathologic

81 studies on the registry are indexed under Neovascularization, Pathologic; 6 are open to participants now.

Browse Neovascularization, Pathologic studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BCVA ≥23 ETDRS letters in study eye at both the Screening and Baseline visits.
  • Evidence, at Screening, of active, angiographically confirmed Choroidal Neovascularization (CNV) secondary to AMD, directly or indirectly affecting the center of the fovea in study eye.
  • No prior anti-VEGF treatment other than aflibercept.

Exclusion criteria

Exclusion Criteria:

  • History of cerebrovascular accident, or myocardial infarction within 3 months of the Screening visit.
  • Any type of systemic disease or its treatment, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.

Exclusion criteria for ocular medical history and conditions for either eye:

  • Any active periocular or ocular infection, or active intraocular inflammation at the time of Screening or Baseline (as per in the Lucentis® Product Monograph).
  • Uncontrolled glaucoma (intraocular pressure [IOP] ≥30 mm Hg on medication or according to Investigator's judgment) at the time of Screening or Baseline
  • Evidence of bilateral active CNV during the Screening Period or at Baseline requiring bilateral anti-VEGF injections.
  • Prior intravitreal injection of ranibizumab or bevacizumab into the study eye and/or prior intravitreal injection of bevacizumab into the fellow eye.

Study eye exclusion criteria:

  • At Baseline, intraocular surgery was performed within the previous 28 days or intraocular surgery is planned at any time during the 6 month study period
  • Cataract (if causing significant visual impairment), aphakia, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization of any other cause than wet AMD (e.g. ocular histoplasmosis, pathologic myopia (≥-8 dioptres)) at the time of Screening and Baseline.
  • Irreversible structural damage involving the center of the fovea (e.g. advanced fibrosis or geographic atrophy) which in the opinion of the Investigator is sufficient to irreversibly impair visual acuity.
  • Polypoidal choroidal vasculopathy (PCV), RPE tear, central serous retinopathy (CSR), or significant vitreomacular traction identified during Screening period or within 4 months of Baseline visit. Note that small vitreomacular adhesions that do not result in deformity of the retina are permitted.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ranibizumab at 0.5 mg

    Single arm, intravitreal injection

    Drug: Ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in Central Subfield Retinal Thickness (CSRT)

    Change (in absolute and percentage terms) in central subfield retinal thickness (CSRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).

    Time frame: at Day 90 (Month 3) and Day 180 (Month 6)

Secondary outcomes

  1. Mean change in Central Subfield Retinal Thickness (CSRT)

    Change (in absolute and percentage terms) in central subfield retinal thickness (CSRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).

    Time frame: Monthly, from baseline to Month 6

  2. Mean change in Subfoveal Retinal Thickness (SRT)

    Change (in absolute and percentage terms) in subfoveal retinal thickness (SRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).

    Time frame: Monthly, from baseline to Month 6

  3. Change in Central Subfield Retinal Volume (CSRV)

    Change (in absolute and percentage terms) in subfoveal retinal thickness (SRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).

    Time frame: Monthly, from baseline to Month 6

  4. Mean change in Subretinal Fluid (SF)

    Measured through Optical Coherence Tomography (OCT).

    Time frame: Monthly, from baseline to Month 6

  5. Mean change in Intra-Retinal Cystoid changes (IRCs) volume

    Measured through Optical Coherence Tomography (OCT).

    Time frame: Monthly, from baseline to Month 6

  6. Mean change in Pigment Epithelial Detachments (PEDs)

    Measured through Optical Coherence Tomography (OCT).

    Time frame: Monthly, from baseline to Month 6

  7. Mean change of Best-Corrected Visual Acuity (BCVA)

    Best-corrected visual acuity (BCVA) will be assessed in a sitting position using subjective refraction and ETDRS-like visual acuity testing charts.

    Time frame: Monthly, from baseline to Month 6

  8. Rate of change in Subfoveal Retinal Thickness (SRT)

    Rates will be assessed with the proportion of patients with changes.

    Time frame: Monthly, from baseline to Month 6

  9. Rate of change in Central Subfield Retinal Thickness (CSRT)

    Rates will be assessed with the proportion of patients with changes.

    Time frame: Monthly, from baseline to Month 6

  10. Rate of change in Intra-Retinal Cystoid (IRCs)

    Rates will be assessed with the proportion of patients with changes.

    Time frame: Monthly, from baseline to Month 6

  11. Rate of change in Pigment Epithelial Detachments (PEDs)

    Rates will be assessed with the proportion of patients with changes.

    Time frame: Monthly, from baseline to Month 6

  12. Rate of Dry Retina

    Rates will be assessed with the proportion of patients with changes.

    Time frame: Monthly, from baseline to Month 6

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2016; primary completion for Dec 2017, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2015
First posted
Dec 18, 2015
StartEst.
Mar 2016
Primary completionEst.
Dec 2017
CompletionEst.
Dec 2017
Last update
Feb 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02634970
Responsible party
Sponsor
First posted
Dec 18, 2015
Start date
Mar 2016 (estimated)
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Feb 15, 2017

Study contacts

Study Director
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion